BCRX Form 4: Amy McKee Converts Retainer to 676 Shares ($8.31)

Rhea-AI Filing Summary

Amy E. McKee, a director of BioCryst Pharmaceuticals, acquired 676 shares of the company's common stock on 08/29/2025 at a price of $8.31 per share. The shares were issued in lieu of 50% of her quarterly cash board retainer of $11,250. After the transaction, Ms. McKee beneficially owns 41,007 shares, held directly. The Form 4 was signed by Alane P. Barnes by power of attorney on 09/03/2025. This filing reports a routine director compensation conversion into equity and does not disclose other changes to ownership or derivative positions.

Insights

Financial Analyst

TL;DR: Routine director equity issuance; small, non-material ownership change from retainer conversion.

The reported issuance of 676 shares at $8.31 reflects compensation paid in stock rather than cash, equivalent to half of a $11,250 quarterly retainer. The transaction increased the reporting person’s direct holdings to 41,007 shares. Given the size of the grant relative to typical public-company market caps and the absence of derivative transactions or other disclosures, this is a routine, non-material event from a financial perspective.

Corporate Governance Expert

TL;DR: Standard governance practice converting board pay to equity; aligns director with shareholders.

Issuing shares in lieu of cash retainers is a common governance tool to align directors with shareholder interests and conserve cash. The Form 4 clearly discloses the conversion and direct ownership level. No departures, new agreements, or exemptions are reported. The disclosure appears complete for this single reporting person filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKee Amy E

(Last) (First) (Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/29/2025		A		676(1)	A	$8.31	41,007	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.

	/s/ Alane P. Barnes, by power of attorney	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BioCryst (BCRX) director Amy E. McKee report on Form 4?

The filing reports that Amy E. McKee acquired 676 shares of BioCryst common stock on 08/29/2025 at $8.31 per share.

Why were the 676 shares issued to Amy E. McKee?

The shares were issued in lieu of 50% of the quarterly cash board retainer of $11,250.

How many BioCryst shares does Amy E. McKee beneficially own after the transaction?

After the reported transaction, she beneficially owns 41,007 shares, held directly.

Was the Form 4 signed and when?

The Form 4 bears a signature by Alane P. Barnes by power of attorney, dated 09/03/2025.

Did the filing report any derivative securities or other transactions?

No. The Form 4 only reports a non-derivative issuance of common stock; no derivative securities are disclosed.